Benjamin J. Zeskind - 03 Feb 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: IMRX
Reported as of: 03 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2026, 08:10:18 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind

Key filing fact

Benjamin J. Zeskind filed Form 4 for Immuneering Corp (IMRX) on 05 Feb 2026.

Key facts

This page summarizes Benjamin J. Zeskind's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 08:10.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001870062 Primary reporting owner

Zeskind Benjamin J.

Relationship: PRESIDENT AND CEO, Director
Address: 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Signature date: 05 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +688,000
Change %
Price: $0.000000
Shares after: 688,000
Date: 03 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 688,000
Exercise price: $4.91
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.